{"id":50504,"date":"2025-12-12T23:01:17","date_gmt":"2025-12-12T15:01:17","guid":{"rendered":"https:\/\/flcube.com\/?p=50504"},"modified":"2025-12-12T23:01:18","modified_gmt":"2025-12-12T15:01:18","slug":"lobemilast-y-3-nda-accepted-by-nmpa-as-first-multi-target-stroke-neuroprotectant","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50504","title":{"rendered":"Lobemilast (Y\u20113) NDA Accepted by NMPA as First Multi\u2011Target Stroke Neuroprotectant"},"content":{"rendered":"\n

Neurodawn Pharmaceutical Co., Ltd.<\/strong> announced that its self\u2011developed Category\u202f1 chemical drug<\/strong>, Y\u20113 for Injection<\/strong> (generic name: Lobemilast<\/strong>), has had its New Drug Application (NDA)<\/strong> officially accepted by China\u2019s National Medical Products Administration (NMPA)<\/strong> for the treatment of Acute Ischemic Stroke (AIS)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
NDA Acceptance Date<\/strong><\/td>11\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>Y\u20113 for Injection (Lobemilast)<\/td><\/tr>
Drug Class<\/strong><\/td>Category\u202f1 chemical drug (innovative small molecule)<\/td><\/tr>
Indication<\/strong><\/td>Acute Ischemic Stroke (AIS)<\/td><\/tr>
Mechanism<\/strong><\/td>Multi\u2011site neuroprotectant targeting PSD95\u2011nNOS\/MPO pathway<\/strong><\/td><\/tr>
Innovation Status<\/strong><\/td>First and only<\/strong> neuroprotectant globally targeting this pathway<\/td><\/tr>
Next Steps<\/strong><\/td>NDA review expected 12\u201115 months; potential approval Q1\u202f2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Profile & Differentiation<\/h2>\n\n\n\n
Attribute<\/th>Lobemilast (Y\u20113)<\/th>Competitive Landscape<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Dual inhibition of PSD95\u2011nNOS<\/strong> and MPO<\/strong> pathways<\/td>Unique, multi\u2011target approach<\/td><\/tr>
Efficacy<\/strong><\/td>Excellent efficacy in ischemic stroke models<\/td>Shows neuroprotection beyond thrombolysis window<\/td><\/tr>
Safety<\/strong><\/td>Preclinical: favorable tolerability; Phase\u202fII data pending<\/td>Reduced risk of off\u2011target effects vs. single\u2011target agents<\/td><\/tr>
Dosing<\/strong><\/td>IV injection; early intervention post\u2011stroke<\/td>Potential for emergency\u2011room administration<\/td><\/tr>
Pipeline Extension<\/strong><\/td>Being explored for post\u2011stroke depression and anxiety<\/strong> prevention<\/td>Expands beyond acute treatment<\/td><\/tr>
R&D Investment<\/strong><\/td>2023: RMB 57.6\u202fM; 2024: RMB 91\u202fM; H1\u202f2025: RMB 52.8\u202fM<\/td>Rapidly accelerating spend<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China AIS Incidence<\/strong><\/td>~\u202f2.0\u202fmillion new cases annually (2024)<\/td><10% receive thrombolysis; high unmet need for neuroprotectants<\/td><\/tr>
China Stroke Care Market<\/strong><\/td>\u00a518\u202fbillion (\u2248\u202fUS$2.5\u202fB)<\/td>Dominated by thrombolytics (alteplase) and antiplatelets<\/td><\/tr>
Neuroprotectant Gap<\/strong><\/td>No approved neuroprotectants in China; global pipeline limited<\/td>Lobemilast could be first\u2011in\u2011class<\/strong> if approved<\/td><\/tr>
Peak Sales Forecast<\/strong><\/td>\u00a52.5\u20113.5\u202fbillion<\/strong> (\u2248\u202fUS$350\u2011490\u202fM) by 2032<\/td>Assumes 30% share of eligible AIS patients not receiving thrombolysis<\/td><\/tr>
Global Expansion Potential<\/strong><\/td>Pathway validated in Western models; potential US\/EU partnering<\/td>PSD95\u2011nNOS\/MPO mechanism aligns with global neuroprotection research<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n